Letters Revolving door between government and industry
Future jobs of FDA’s haematology-oncology reviewers
BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i5055 (Published 27 September 2016) Cite this as: BMJ 2016;354:i5055
- Jeffrey Bien, internal medicine resident1,
- Vinay Prasad, assistant professor of medicine1
- 1Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
- prasad{at}ohsu.edu
Medical reviewers at the US Food and Drug Administration are vital to effective regulation, interpreting whether a drug’s harm-benefit balance is favourable. When regulators leave government, some work or consult for the industries they regulated.1 2 Although this “revolving door” has been criticised,1 2 it has not been studied. We sought to measure how often it occurs at the FDA.
Using the set of FDA haematology-oncology drug approvals listed on its …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.
